HIV 1 News and Research

RSS

Researchers discover series of compounds possessing anti-HIV activity

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

18 Dec 2013

MTN receives $70M to develop and test products that aim to reduce spread of HIV

With funding of $70 million to support its effort into 2021, the Microbicide Trials Network (MTN) will continue to develop and test products that aim to reduce the spread of HIV, the virus that causes AIDS, federal officials announced yesterday.

17 Dec 2013

HIV self-test screening strategy: an interview with Dr. Nitika Pant Pai, McGill University

Conventional health facility based HIV testing is plagued with poor rates of testing and has been around for the past 15+ years. Further, about 40-60% of individuals tested in facilities are lost to follow up.

17 Dec 2013

Investigators, CTUs chosen to lead five HIV/AIDS clinical trials networks through 2021

Principal investigators and clinical trials units have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021. The effort is directed and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Total funding for the networks' leadership and the CTUs is expected to reach $225 million in 2014, the first year of operation.

17 Dec 2013

Two existing drugs show promise as potential treatments for cervical cancer

Two existing drugs - one the active ingredient in an anti-fungal medication and the other now used to control iron levels in the blood - both show promise as potential treatments for cervical cancer, according to newly published research by scientists at Rutgers New Jersey Medical School.

17 Dec 2013

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Testing the efficacy of vaccines in clinical trials takes years, even decades. Yet challenging infections like HIV, malaria and dengue are striking today. To speed up vaccine testing, scientists at the Emory Vaccine Center have established a goal of creating a "vaccine gene chip."

17 Dec 2013

Secondary conditions can become deadly and affect how long HIV patients stay in hospital

A University of Arkansas researcher and her colleagues have found that secondary conditions and diseases that could become deadly significantly affect how long HIV patients stay in the hospital.

17 Dec 2013

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

The National Institute of Allergy and Infectious Diseases has awarded two seven-year grants to Brigham and Women's Hospital to fund the AIDS Clinical Trial Group Network.

16 Dec 2013

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

A Massachusetts General Hospital research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men. In the Dec. 1 issue of the Journal of Infectious Diseases the investigators report finding that HIV-infected women had a greater prevalence of the type of coronary artery plaque most vulnerable to rupture than did uninfected women.

14 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Understanding long-term clinical stability in hemophilia patients living with HIV

People with the genetic blood clotting disorder hemophilia who have been infected with HIV for decades have an increased proportion of immune cells in their blood that specifically target HIV. This protective immune response helps chronically infected hemophilia patients survive, even during periods of HIV activity, according to a study published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

12 Dec 2013

Scientists use new method to map response of every salmonella gene to conditions in human body

Scientists have used a new method to map the response of every salmonella gene to conditions in the human body, providing new insight into how the bacteria triggers infection.

12 Dec 2013

Group says Obamacare plans discourage HIV patients from enrolling

A coalition of AIDS organizations is asking the Obama administration to investigate whether some insurers are trying to discourage HIV-infected patients from enrolling in their policies by failing to cover some AIDS drugs or through what it called "egregious cost-sharing designs." Other stories explore the law's impact on African-Americans and small businesses.

12 Dec 2013

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

AstraZeneca and Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) recommends the investigational medicine metreleptin for the treatment of pediatric and adult patients with generalized lipodystrophy (LD).

12 Dec 2013

HIV stigma: an interview with Dr. Vargas-Jackson, M.D. Howard University Hospital

Stigma has been defined as a social opportunistic disease that attaches to many illnesses and increases morbidity and mortality rates. Stigma is the shame or disgrace attached to illnesses and diseases regarded as socially unacceptable.

11 Dec 2013

Results-Based Financing for Health can get 20% more health care with same funds

Countries and major donors are changing the way they finance maternal and child, malaria, tuberculosis and HIV/AIDS health programs in low-income countries to increase their impact.

11 Dec 2013

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load.

11 Dec 2013

Duke University receives $2.9M grant to develop HIV vaccine candidate

Duke University has received a grant of up to $2.9 million from the Bill & Melinda Gates Foundation to produce an HIV vaccine candidate that will be tested in humans.

10 Dec 2013

Study finds large degree of genetic variation amongst M. tuberculosis in humans in Zambia

In Zambia, the incidence of all forms of human tuberculosis is estimated to be 444 per 100,000. There is also a high incidence of HIV and AIDS in the country. In the Kafue area, a high incidence of Mycobacterium bovis in both cattle and the Kafue lechwe antilope has been detected. This bacterium can infect humans and has been found in humans in the studied region of Namwala. Mycobacterium tuberculosis, which is the main cause of human tuberculosis, has also been detected in cattle in this region.

10 Dec 2013

IBN and IBM discover new medical application for converted PET bottles

Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research - Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles.

10 Dec 2013

HIV 1 News and Research

Researchers discover series of compounds possessing anti-HIV activity

MTN receives $70M to develop and test products that aim to reduce spread of HIV

HIV self-test screening strategy: an interview with Dr. Nitika Pant Pai, McGill University

Investigators, CTUs chosen to lead five HIV/AIDS clinical trials networks through 2021

Two existing drugs show promise as potential treatments for cervical cancer

Scientists establish a goal of creating vaccine gene chip to speed up vaccine testing

Secondary conditions can become deadly and affect how long HIV patients stay in hospital

BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

Possible mechanism behind elevated risk of cardiovascular disease discovered in HIV-infected women

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Understanding long-term clinical stability in hemophilia patients living with HIV

Scientists use new method to map response of every salmonella gene to conditions in human body

Group says Obamacare plans discourage HIV patients from enrolling

FDA Advisory Committee recommends metreleptin for treatment of generalized lipodystrophy

HIV stigma: an interview with Dr. Vargas-Jackson, M.D. Howard University Hospital

Results-Based Financing for Health can get 20% more health care with same funds

Detectable blood viral load increases prevalence of heart disease

Duke University receives $2.9M grant to develop HIV vaccine candidate

Study finds large degree of genetic variation amongst M. tuberculosis in humans in Zambia

IBN and IBM discover new medical application for converted PET bottles

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Automating research - solutions and best practices

Latest News